During the recent session, Verona Pharma Plc ADR (NASDAQ:VRNA)’s traded shares were 0.87 million, with the beta value of the company hitting 0.19. At the last check today, the stock’s price was $79.61, reflecting an intraday gain of 2.74% or $2.12. The 52-week high for the VRNA share is $77.98, that puts it up 2.05 from that peak though still a striking 85.69% gain since the share price plummeted to a 52-week low of $11.39. The company’s market capitalization is $6.78B, and the average intraday trading volume over the past 10 days was 1.1 million shares, and the average trade volume was 1.36 million shares over the past three months.
Verona Pharma Plc ADR (VRNA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. VRNA has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.39.
Verona Pharma Plc ADR (NASDAQ:VRNA) trade information
Verona Pharma Plc ADR (VRNA) registered a 2.74% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.74% in intraday trading to $79.61, hitting a weekly high. The stock’s 5-day price performance is 9.52%, and it has moved by 10.46% in 30 days. Based on these gigs, the overall price performance for the year is 540.47%. The short interest in Verona Pharma Plc ADR (NASDAQ:VRNA) is 8.07 million shares and it means that shorts have 5.71 day(s) to cover.
The consensus price target of analysts on Wall Street is $77.5, which implies a decrease of -2.72% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $74 and $83 respectively. As a result, VRNA is trading at a discount of -4.26% off the target high and 7.05% off the low.
Verona Pharma Plc ADR (VRNA) estimates and forecasts
In the rating firms’ projections, revenue will increase 813.37% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 68.24M as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 88M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 7.21%. While earnings are projected to return 153.85% in 2025.
VRNA Dividends
Verona Pharma Plc ADR is due to release its next quarterly earnings on 2025-Apr-28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Verona Pharma Plc ADR (NASDAQ:VRNA)’s Major holders
Verona Pharma Plc ADR insiders own 11.95% of total outstanding shares while institutional holders control 90.84%, with the float percentage being 103.16%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 316.0 institutions own stock in it. As of 2024-06-30, the company held over 7.63 million shares (or 1.1775% of all shares), a total value of $110.37 million in shares.
The next largest institutional holding, with 0.86 million shares, is of MORGAN STANLEY’s that is approximately 1.0663% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $12.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Verona Pharma Plc ADR (VRNA) shares are MUTUAL FUND SERIES TRUST-Eventide Gilead Fund and MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund . Data provided on Dec 31, 2024 indicates that MUTUAL FUND SERIES TRUST-Eventide Gilead Fund owns about 1.89 shares. This amounts to just over 2.22 percent of the company’s overall shares, with a $150.08 million market value. The same data shows that the other fund manager holds slightly less at 1.23, or about 1.44% of the stock, which is worth about $97.69 million.
